ONC.TO - Oncolytics Biotech Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.57
-0.01 (-1.72%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.58
Open0.58
Bid0.57 x 0
Ask0.58 x 0
Day's Range0.55 - 0.60
52 Week Range0.19 - 1.13
Volume158,153
Avg. Volume163,055
Market Cap79.47M
Beta2.40
PE Ratio (TTM)-4.25
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Researchlast month

    Oncolytics’ (ONCYF) End of Phase II Meeting

    By John Vandermosten, CFA OTC:ONCYF TSX:ONC.V Oncolytics Biotech (OTC:ONCYF) (TSX:ONC.TO) announced a successful end of Phase II meeting with the FDA in a September 18 press release.  The purpose of the ...

  • Zacks Small Cap Research2 months ago

    Oncolytics’ (ONCYF) Second Quarter Results

    Oncolytics Biotech, Incorporated’s (ONCYF) second quarter began with a rush of activity as the company presented compelling data from its IND 213 study at AACR followed by an announcement of fast track designation by the FDA and presentation at ASCO in May.  The strong data from the metastatic breast cancer trial indicated a 17 month benefit from REOLYSIN (compared to 10 months for chemotherapy alone) and opens the opportunity for breakthrough designation which could be announced in October.  In preparation for a Phase III trial, Oncolytics raised additional capital in May which is expected to fund operations until late next year. The second half of 2017 will emphasize the interactions with the FDA and how this will impact the design of the Phase III trial for metastatic breast cancer.  There is also the possibility to receive breakthrough designation which will expedite the FDA’s review of REOLYSIN.  Potential collaborators are watching this process closely and we anticipate that there will be more to announce regarding a partner for the Phase III trial before the end of the year.

  • Associated Press3 months ago

    Oncolytics reports 2Q loss

    On a per-share basis, the Calgary, Alberta-based company said it had a loss of 2 cents. The company's shares closed at 40 cents. A year ago, they were trading at 32 cents. _____ This story was generated ...

  • Zacks Small Cap Research4 months ago

    Oncolytics (ONCYF) Raises CAD$11 Million

    By John Vandermosten, CFA OTC:ONCYF Public Offering of Shares Strengthens Balance Sheet In late May, 2017, Oncolytics Biotech, Inc. (OTC:ONCYF) announced and priced 16.4 million units at CAD$0.70 per share ...

  • Newsfile5 months ago

    IIROC Trade Halt - Oncolytics Biotech Inc. Common share purchase warrants

    Toronto, Ontario--(Newsfile Corp. - June 1, 2017) - The following issues have been halted by IIROC: Company:  Oncolytics Biotech Inc. Common share purchase warrants TSX Symbol: ONC.WT ...

  • Zacks Small Cap Research5 months ago

    ONCYF: FDA Grants Fast Track Authority

    By John Vandermosten, CFA OTC:ONCYF On May 8th, Oncolytics Biotech, Inc. (OTC:ONCYF) announced that the FDA had granted Fast Track status to REOLYSIN for the treatment of metastatic breast cancer.  Fast ...

  • Associated Press6 months ago

    Oncolytics reports 1Q loss

    The Calgary, Alberta-based company said it had a loss of 2 cents per share. The company's shares closed at 61 cents. A year ago, they were trading at 53 cents. _____ This story was generated by Automated ...

  • Zacks Small Cap Research6 months ago

    ONCYF: REOLYSIN Clinical Development Plan

    On April 12, 2017, Oncolytics Biotech, Inc. (ONCYF) provided an outline of their path forward for developing REOLYSIN, their proprietary oncolytic virus used in the treatment of several cancers.  The company’s primary goal is to obtain regulatory approval for REOLYSIN in metastatic breast cancer based on the data presented at the American Academy of Cancer Research (AACR) Annual Meeting in early April.  Oncolytics will also develop REOLYSIN for other indications and in combination with other agents, such as checkpoint inhibitors and immunomodulatory imide drugs (IMiDs).